Thomas Wagner has been a consultant in nuclear medicine at the Royal Free Hospital since 2011 where he is the PET-CT lead. His main interests and clinical activity are PET-CT in lung cancer, breast cancer, prostate cancer and haematological malignancies and he provides nuclear medicine input in the weekly MDTs covering these malignancies. He also has specialist interest in neurology, infectious and inflammatory disorders. He has an interest in VQ scans and has published articles on that topic. His current research focuses on investigating the role of florbetapir as a potential new tracer for systemic amyloidosis. He is principal investigator for a research study investigating the value of dedicated breast PET in indeterminate breast lesions. He has co-edited an ebook on PET-CT in infectious and inflammatory disorders and numerous original articles in international peer-reviewed journals.
